The main goals of therapy for patients with heart failure with preserved ejection fraction are to address the signs and symptoms of heart failure, improve quality of life, and reduce the risk of ...

Patients with heart failure with preserved ejection fraction (HFpEF) present with non-specific symptoms ... The intervention will focus on improving diagnostic process, decreasing physician burden and ...

The new approach is designed to create a connection between the left and right atrial chambers of the heart in a single ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

What left ventricular ejection fraction (LVEF) range is a component ... and increased plasma flow in the kidneys leads to an increase in the glomerular filtration rate. Changes in renal tubular ...

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ZSF1 studies, which are common models to study key features of heart failure ...

which minimized the confounder that patients with systolic heart failure whose ejection fraction might have improved with concurrent treatments were enrolled into this study. I-PRESERVE ...